[en] Specific soluble biomarkers can be powerful tools for the diagnosis, prognosis and personalized management of osteoarthritis (OA). Biomarkers are potential indicators of the effect of a drug on cartilage metabolism and provide crucial information about the mechanisms of drug action. In this review, we address key questions concerning the use of biomarkers in OA management: Why do we need soluble biomarkers? What are the most widely investigated biomarkers derived from cartilage extracellular matrix? What are the most common pitfalls in interpreting soluble biomarker measurements? What are the perspectives and future research directions in this field? We review current evidence to propose that cartilage-derived soluble biomarkers are complementary "drug development tools" that can be applied during drug development from preclinical research to clinical evaluation. In the future, such biomarkers could be surrogate markers of clinical and/or imaging outcomes. Successful standardization and implementation of automated biomarker assays will facilitate their use in companion diagnostics in the context of personalized medicine for enhanced management of OA.
Research center :
d‐BRU - Dental Biomaterials Research Unit - ULiège [BE]
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves ; Université de Liège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Sanchez, Christelle ; Université de Liège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)
Bay-Jensen, A. C.
Mobasheri, A.
Language :
English
Title :
Osteoarthritis biomarkers derived from cartilage extracellular matrix: Current status and future perspectives.
Publication date :
June 2016
Journal title :
Annals of Physical and Rehabilitation Medicine
ISSN :
1877-0657
eISSN :
1877-0665
Publisher :
Elsevier Masson, Paris, France
Volume :
59
Issue :
3
Pages :
145-148
Peer reviewed :
Peer Reviewed verified by ORBi
European Projects :
FP7 - 305815 - D-BOARD - Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases
Funders :
CE - Commission Européenne [BE]
Commentary :
Copyright (c) 2016 Elsevier Masson SAS. All rights reserved.
Veronese N., Trevisan C., De Rui M., Bolzetta F., Maggi S., Zambon S., et al. Osteoarthritis increases the risk of cardiovascular diseases in the elderly: the progetto veneto anziano study. Arthritis Rheumatol 2015, 10.1002/art.39564.
Eymard F., Parsons C., Edwards M.H., Petit-Dop F., Reginster J.Y., Bruyère O., et al. Diabetes is a risk factor for knee osteoarthritis progression. Osteoarthritis Cartilage 2015, 23:851-859.
Heuts P.H., Vlaeyen J.W., Roelofs J., de Bie R.A., Aretz K., van Weel C., et al. Pain-related fear and daily functioning in patients with osteoarthritis. Pain 2004, 110:228-235.
Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013, 21:16-21.
Attur M., Krasnokutsky S., Statnikov A., Samuels J., Li Z., Friese O., et al. Low-grade inflammation in symptomatic knee osteoarthritis: prognostic value of inflammatory plasma lipids and peripheral blood leukocyte biomarkers. Arthritis Rheumatol 2015, 67:2905-2915.
Bauer D.C., Hunter D.J., Abramson S.B., Attur M., Corr M., Felson D., et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006, 14:723-727.
Kraus V.B., Burnett B., Coindreau J., Cottrell S., Eyre D., Gendreau M., et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage 2011, 19:515-542.
Kraus V.B., Blanco F.J., Englund M., Henrotin Y., Lohmander L.S., Losina E., et al. OARSI clinical trials recommendations: soluble biomarker assessments in clinical trials in osteoarthritis. Osteoarthritis Cartilage 2015, 23:686-697.
Bay-Jensen A.C., Reker D., Kjelgaard-Petersen C.F., Mobasheri A., Karsdal M.A., Ladel C., et al. Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. Osteoarthritis Cartilage 2016, 24:9-20.
Henrotin Y., Addison S., Kraus V., Deberg M. Type II collagen markers in osteoarthritis: what do they indicate?. Curr Opin Rheumatol 2007, 19:444-450.
van Spil W.E., DeGroot J., Lems W.F., Oostveen J.C., Lafeber F.P. Serum and urinary biochemical markers for knee and hip osteoarthritis: a systematic review applying the consensus BIPED criteria. Osteoarthritis Cartilage 2010, 18:605-612.
Verma P., Dalal K.J. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker. Orthop Res 2013, 31:999-1006.
Henrotin Y., Deberg M., Mathy-Hartert M., Deby-Dupont G. Biochemical biomarkers of oxidative collagen damage. Adv Clin Chem 2009, 49:31-55.
Svoboda S.J., Harvey T.M., Owens B.D., Brechue W.F., Tarwater P.M., Cameron K.L. Changes in serum biomarkers of cartilage turnover after anterior cruciate ligament injury. Am J Sports Med 2013, 41:2108-2116.
Larsson S., Lohmander L.S., Struglics A. An ARGS-aggrecan assay for analysis in blood and synovial fluid. Osteoarthritis Cartilage 2014, 22:242-249.
Henrotin Y., Gharbi M., Mazzucchelli G., Dubuc J.E., De Pauw E., Deberg M. Fibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis. Arthritis Rheum 2012, 64:2260-2267.
Albig A.R., Neil J.R., Schiemann W.P. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006, 66:2621-2629.
Klenotic P.A., Munier F.L., Marmorstein L.Y., Anand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 2004, 279:30469-30473.
Djokic J., Fagotto-Kaufmann C., Bartels R., Nelea V., Reinhardt D.P. Fibulin-3, -4, and -5 are highly susceptible to proteolysis, interact with cells and heparin, and form multimers. J Biol Chem 2013, 288:22821-22835.
Sharif M., Granell R., Johansen J., Clarke S., Elson C., Kirwan J.R. Serum cartilage oligomeric matrix protein and other biomarker profiles in tibiofemoral and patellofemoral osteoarthritis of the knee. Rheumatology (Oxford) 2006, 45:522-526.
Gharbi M., Deberg M., Henrotin Y. Application for proteomic techniques in studying osteoarthritis: a review. Front Physiol 2011, 2:90.
